P2X3 receptor antagonist
Gefapixant
Brand names: Lyfnua
Adult dose
Dose: 45mg PO BD
Route: PO
Frequency: BD
Clinical pearls
- Refractory or unexplained chronic cough in adults — specialist clinics
- Taste disturbance is the principal limitation
Contraindications
- Hypersensitivity
Side effects
- Dysgeusia / ageusia (very common — often dose-limiting)
- Hypoaesthesia of tongue
- Nausea
Interactions
- OCT2 substrates (metformin — minor)
Reference: BNF; SmPC; https://bnf.nice.org.uk/drugs/gefapixant/. Verify against your local formulary and the latest BNF before prescribing.
Related
Curated clinical cross-links plus same-class fallbacks.
Pathways
- Acute Asthma in Adults · BTS/SIGN British Guideline on Asthma 2019; NICE NG80
- Pulmonary Embolism Assessment · NICE NG158; ESC 2019 PE Guidelines
- Acute Exacerbation of COPD (AECOPD) · NICE NG115; GOLD 2024
- Spontaneous Pneumothorax (Adult) · BTS Pleural Disease 2023
- Atypical Pneumonia (Legionella / Mycoplasma / Chlamydophila) · BTS 2023; IDSA
- COPD Exacerbation Management · NICE NG115 / GOLD 2024